Patent intelligence · US
US 11834507
Anti-MET agonist antibody for use in the treatment of colorectal cancer
Anti-MET agonist antibody for use in the treatment of colorectal cancer
Patent details — US 11834507
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2023
- Expiration
- Nov 30, 2043
- Applicant
- AGOMAB THERAPEUTICS
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 11834507 (Anti-MET agonist antibody for use in the treatment of colorectal cancer) is held by AGOMAB THERAPEUTICS. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AGOMAB THERAPEUTICS
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from AGOMAB THERAPEUTICS
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11834507?
US 11834507 (Anti-MET agonist antibody for use in the treatment of colorectal cancer) is held by AGOMAB THERAPEUTICS. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11834507?
AGOMAB THERAPEUTICS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11834507 expire?
Our index shows an expiration date of Nov 30, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.